# Oncocyte Corporation (OCX)

Source: https://www.quantisnow.com/company/OCX
Generated: 2026-11-12T11:36:02.434Z

- Ticker: OCX
- Exchange: AMEX
- Sector: Health Care
- Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Website: oncocyte.com

## About

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.

## Latest OCX news and filings

- 2026-05-18 13:02 UTC [Leadership Update] [InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors](https://www.quantisnow.com/insight/intervenn-appoints-industry-leaders-alec-ford-and-mitch-levine-to-6559459)
- 2025-07-03 20:05 UTC [SEC Form 4] [Director Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)](https://www.quantisnow.com/insight/director-arno-andrew-was-granted-55000-shares-increasing-direct-ownership-6110903)
- 2025-07-03 20:05 UTC [SEC Form 4] [Director Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)](https://www.quantisnow.com/insight/director-silverman-lou-was-granted-35000-shares-increasing-direct-ownership-6110893)
- 2025-07-03 20:05 UTC [SEC Form 4] [Director Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)](https://www.quantisnow.com/insight/director-last-andrew-j-was-granted-35000-shares-increasing-direct-6110888)
- 2025-07-02 21:01 UTC [SEC Form 8-K] [Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/oncocyte-corporation-filed-sec-form-8-k-submission-of-matters-to-6109132)
- 2025-06-17 11:33 UTC [SEC Form 8-K] [Oncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oncocyte-corporation-filed-sec-form-8-k-amendments-to-articles-of-6089167)
- 2025-06-17 11:00 UTC [Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville](https://www.quantisnow.com/insight/oncocyte-changes-name-to-insight-molecular-diagnostics-inc-imdx-moves-6089114)
- 2025-05-19 20:05 UTC [Conference Announcement] [Medicare Boosts Reimbursement for Oncocyte's Flagship Technology](https://www.quantisnow.com/insight/medicare-boosts-reimbursement-for-oncocytes-flagship-technology-6047589)
- 2025-05-14 21:08 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Oncocyte Corporation](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-oncocyte-corporation-6039840)
- 2025-05-14 21:07 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Oncocyte Corporation](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-oncocyte-corporation-6039835)
- 2025-05-12 20:12 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Oncocyte Corporation](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-oncocyte-corporation-6033149)
- 2025-05-12 20:10 UTC [SEC Form 8-K] [Oncocyte Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oncocyte-corporation-filed-sec-form-8-k-results-of-operations-and-6033103)
- 2025-05-12 20:05 UTC [Public Offering] [Oncocyte Reports Q1 2025 Results and Business Progress](https://www.quantisnow.com/insight/oncocyte-reports-q1-2025-results-and-business-progress-6032835)
- 2025-05-09 20:06 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Oncocyte Corporation](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-oncocyte-corporation-6030206)
- 2025-05-07 20:10 UTC [Earnings Date] [Oncocyte to Release First Quarter 2025 Results on May 12, 2025](https://www.quantisnow.com/insight/oncocyte-to-release-first-quarter-2025-results-on-may-12-6024068)
- 2025-04-30 12:30 UTC [Earnings Date] [Oncocyte Provides Positive Update on Clinical Trial Progress](https://www.quantisnow.com/insight/oncocyte-provides-positive-update-on-clinical-trial-progress-6009142)
- 2025-04-29 12:30 UTC [Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity](https://www.quantisnow.com/insight/oncocytes-proprietary-assay-demonstrates-long-term-clinical-validity-6006284)
- 2025-04-24 21:00 UTC [Earnings Date] [STAAR Surgical Announces Changes to Board of Directors](https://www.quantisnow.com/insight/staar-surgical-announces-changes-to-board-of-directors-6001184)
- 2025-04-17 21:17 UTC [SEC Form 8-K] [Oncocyte Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oncocyte-corporation-filed-sec-form-8-k-changes-in-registrants-certifying-5992876)
- 2025-04-08 10:10 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Oncocyte Corporation](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-oncocyte-corporation-5980428)
- 2025-04-08 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Oncocyte Corporation](https://www.quantisnow.com/insight/sec-form-effect-filed-by-oncocyte-corporation-5980403)
- 2025-04-02 12:45 UTC [Conference Announcement] [Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference](https://www.quantisnow.com/insight/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference-5971301)
- 2025-03-31 17:25 UTC [SEC Form S-1] [SEC Form S-1 filed by Oncocyte Corporation](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-oncocyte-corporation-5966700)
- 2025-03-28 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer James Andrea S.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-james-andrea-5964717)
- 2025-03-28 20:05 UTC [SEC Form 4] [SEC Form 4 filed by VP ACCT, Cntlr, Treasurer, PAO Liu James Yang](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-acct-cntlr-treasurer-pao-5964716)
- 2025-03-28 20:05 UTC [SEC Form 4] [SEC Form 4 filed by CEO and President Riggs Josh](https://www.quantisnow.com/insight/sec-form-4-filed-by-ceo-and-president-riggs-josh-5964711)
- 2025-03-28 12:35 UTC [Analyst Coverage Initiated] [Lake Street initiated coverage on OncoCyte with a new price target](https://www.quantisnow.com/insight/lake-street-initiated-coverage-on-oncocyte-with-a-new-price-5964284)
- 2025-03-24 20:16 UTC [SEC Form 10-K] [SEC Form 10-K filed by Oncocyte Corporation](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-oncocyte-corporation-5957710)
- 2025-03-24 20:10 UTC [SEC Form 8-K] [Oncocyte Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oncocyte-corporation-filed-sec-form-8-k-results-of-operations-and-5957654)
- 2025-03-24 20:05 UTC [Public Offering] [Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts](https://www.quantisnow.com/insight/oncocyte-reports-successful-2024-sets-stage-for-2025-catalysts-5957547)
- 2025-03-18 20:05 UTC [Earnings Date] [Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025](https://www.quantisnow.com/insight/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-5949482)
- 2025-03-10 20:05 UTC [SEC Form 8-K] [Oncocyte Corporation filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/oncocyte-corporation-filed-sec-form-8-k-leadership-update-5935701)
- 2025-03-05 00:06 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Oncocyte Corporation](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-oncocyte-corporation-5925988)
- 2025-02-24 11:03 UTC [SEC Form D] [SEC Form D filed by Oncocyte Corporation](https://www.quantisnow.com/insight/sec-form-d-filed-by-oncocyte-corporation-5904140)
- 2025-02-20 21:02 UTC [Leadership Update] [Veradigm Announces Board Expansion and Changes](https://www.quantisnow.com/insight/veradigm-announces-board-expansion-and-changes-5899970)
- 2025-02-14 19:41 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Oncocyte Corporation](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-oncocyte-corporation-5890057)
- 2025-02-12 00:00 UTC [Insider Buy] [Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-james-andrea-s-bought-200000-worth-of-5882909)
- 2025-02-11 22:00 UTC [Insider Buy] [Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-smith-patrick-w-bought-2209080-worth-of-shares-5882558)
- 2025-02-11 13:30 UTC [Conference Announcement] [Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference](https://www.quantisnow.com/insight/oncocyte-to-participate-in-btig-medtech-digital-health-life-science-5881175)
- 2025-02-11 01:46 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Oncocyte Corporation](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-oncocyte-corporation-5880708)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OCX
- Earnings history: https://www.quantisnow.com/earnings/OCX
- Dividend history: https://www.quantisnow.com/dividends/OCX
- Insider transactions: https://www.quantisnow.com/insiders/OCX
- Options chain: https://www.quantisnow.com/options/OCX
- SEC 8-K filings only: https://www.quantisnow.com/company/OCX/8-k
- RSS and alerts for OCX: https://www.quantisnow.com/docs/rss-feeds.md